[ad_1]
New York: Researchers, including an Indian physician, have been able to obtain higher doses of radiation for a much shorter period of time while retaining the same positive results as those achieved with a much longer-origin treatment.
The study showed that this type of radiation – stereotactic body radiotherapy – is a form of external beam radiotherapy, which reduces the duration of treatment from 45 days to four to five days without it being possible to demonstrate that it causes increased toxicity in the long run.
"Most men with low-risk or intermediate-risk prostate cancer are subject to conventional radiation, which forces them to come daily for treatment and lasts an average of nine weeks," said the doctor. Lead author Amar Kishan, Assistant Professor at the University of California at Los Angeles. , in the USA.
"Thanks to improvements in modern technology, we have found that stereotaxic body radiation therapy, which uses a higher dose of radiation, can be safely and effectively delivered in a much shorter time without additional toxicity or compromised chances. of healing, "says Kishan.
For the study, the team included 2,142 men with low-risk or intermediate-risk prostate cancer treated with stereotactic radiotherapy. They were followed for a median of 6.9 years.
Nearly 53% of men had a low-risk disease, 32% a less aggressive intermediate-risk disease, and 12% a more aggressive form of intermediate-risk disease.
In addition, the recurrence rate for men with low-risk disease was 4.5%, of which 8.6% for the less aggressive intermediate-risk group and 14.9% for the more aggressive intermediate-risk group, according to the journal JAMA Network Open. shown.
Overall, the recurrence rate for intermediate-risk diseases was 10.2%.
These rates are essentially the same as the rates observed after more conventional forms of radiation, which account for about 4-5% of low-risk diseases and 10-15% of intermediate-risk diseases.
This method is both safe and effective and could be a viable treatment option for men at low or intermediate prostate cancer risk, the study suggested.
Source: IANS
Source link
